Zhang Jian

Research areas: Clinical and basic research on recurrent and metastatic breast cancer, clinical research on new anti-tumor drugs, and brain metastases of triple-negative breast cancer.

Cutting-edge technology: Leading the development of the "ABC" three-drug combination regimen for treating TNBC brain metastases, achieving an intracranial objective response rate of 77.1% and a median overall survival of 21 months, with results published in JCO. At the 2028 ESMO BC conference, phase II data on Pumitamig combined with BNT325 as first-line treatment for TNBC were presented, confirming an objective response rate of 7.7% and exploring a novel "chemotherapy-free" treatment modality. Has presided over 3 National Natural Science Foundation of China projects and over 20 projects including the Shanghai Natural Science Foundation, and has published 71 SCI papers as first/corresponding author.

Specializes in treating: breast cancer, triple-negative breast cancer, and brain metastases from breast cancer.

Academic Highlights and Core Values: Medical Director of the Phase I Clinical Trial Ward at Fudan University Cancer Hospital; Director of the Clinical Research Center/Executive Deputy Director of the Department of Medical Oncology at Fudan University Cancer Hospital (Fujian Branch); Shanghai "Medical Rising Star" Outstanding Young Talent; one of the "Top Ten Medical Pioneer Experts" in 2023; and a recipient of the third "People's Good Doctor" award. He holds an internationally leading position in the treatment of brain metastases from triple-negative breast cancer, and his "ABC" regimen provides a "Chinese solution" for TNBC brain metastases patients worldwide.